Fishman Mayer相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Approaches to Treating High Risk and Advanced Renal Cell Carcinoma (RCC): Key Trial Data That Impacts Treatment Decisions in the Clinic

高危及晚期肾细胞癌（RCC）的治疗方法：影响临床治疗决策的关键试验数据

期刊:Research and Reports in Urology

影响因子:2.7

doi:10.2147/RRU.S457287

Chatzkel, Jonathan; Fishman, Mayer; Ramnaraign, Brian; O'Malley, Padraic; Sonpavde, Guru P

细胞生物学

发表日期：2024

文献求助收藏

A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience

免疫治疗时代之前转移性肾细胞癌初始治疗选择的前瞻性多中心评估：MaRCC注册研究的经验

期刊:Clinical Genitourinary Cancer

影响因子:2.7

doi:10.1016/j.clgc.2021.07.002

Costello, Brian A; Bhavsar, Nrupen A; Zakharia, Yousef; Pal, Sumanta K; Vaishampayan, Ulka; Jim, Heather; Fishman, Mayer N; Molina, Ana M; Kyriakopoulos, Christos E; Tsao, Che-Kai; Appleman, Leonard J; Gartrell, Benjamin A; Hussain, Arif; Stadler, Walter M; Agarwal, Neeraj; Pachynski, Russell K; Hutson, Thomas E; Hammers, Hans J; Ryan, Christopher W; Mardekian, Jack; Borham, Azah; George, Daniel J; Harrison, Michael R

细胞生物学

免疫/内分泌

发表日期：2022

文献求助收藏

Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial

阿昔替尼联合帕博利珠单抗治疗晚期肾细胞癌患者：一项 Ib 期试验的长期疗效和安全性

期刊:European Journal of Cancer

影响因子:7.1

doi:10.1016/j.ejca.2020.12.009

Atkins, Michael B; Plimack, Elizabeth R; Puzanov, Igor; Fishman, Mayer N; McDermott, David F; Cho, Daniel C; Vaishampayan, Ulka; George, Saby; Tarazi, Jamal C; Duggan, William; Perini, Rodolfo; Thakur, Mahgull; Fernandez, Kathrine C; Choueiri, Toni K

细胞生物学

发表日期：2021

文献求助收藏

Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)

转移性肾细胞癌的主动监测：一项前瞻性观察研究的结果（MaRCC）

影响因子:5.1

doi:10.1002/cncr.33494

Harrison, Michael R; Costello, Brian A; Bhavsar, Nrupen A; Vaishampayan, Ulka; Pal, Sumanta K; Zakharia, Yousef; Jim, Heather S L; Fishman, Mayer N; Molina, Ana M; Kyriakopoulos, Christos E; Tsao, Che-Kai; Appleman, Leonard J; Gartrell, Benjamin A; Hussain, Arif; Stadler, Walter M; Agarwal, Neeraj; Pachynski, Russell K; Hutson, Thomas E; Hammers, Hans J; Ryan, Christopher W; Inman, Brant A; Mardekian, Jack; Borham, Azah; George, Daniel J

细胞生物学

发表日期：2021

文献求助收藏

Systemic inflammation and symptomatology in patients with prostate cancer treated with androgen deprivation therapy: Preliminary findings

接受雄激素剥夺疗法治疗的前列腺癌患者的全身炎症和症状：初步研究结果

影响因子:5.1

doi:10.1002/cncr.33397

Hoogland, Aasha I; Jim, Heather S L; Gonzalez, Brian D; Small, Brent J; Gilvary, Danielle; Breen, Elizabeth C; Bower, Julienne E; Fishman, Mayer; Zachariah, Babu; Jacobsen, Paul B

免疫/内分泌

发表日期：2021

文献求助收藏

A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma

一项单臂、多中心、II期临床研究，评估乐伐替尼联合依维莫司治疗晚期非透明细胞肾细胞癌患者的疗效

doi:10.1016/j.eururo.2021.03.015

Hutson, Thomas E; Michaelson, M Dror; Kuzel, Timothy M; Agarwal, Neeraj; Molina, Ana M; Hsieh, James J; Vaishampayan, Ulka N; Xie, Ran; Bapat, Urmi; Ye, Weifei; Jain, Rohit K; Fishman, Mayer N

细胞生物学

发表日期：2021

文献求助收藏

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

在PD1或PDL1抑制剂治疗后，采用高剂量白细胞介素-2（HD IL-2）治疗转移性黑色素瘤和肾细胞癌

期刊:Journal for ImmunoTherapy of Cancer

影响因子:10.6

doi:10.1186/s40425-019-0522-3

Buchbinder, Elizabeth I; Dutcher, Janice P; Daniels, Gregory A; Curti, Brendan D; Patel, Sapna P; Holtan, Shernan G; Miletello, Gerald P; Fishman, Mayer N; Gonzalez, Rene; Clark, Joseph I; Richart, John M; Lao, Christopher D; Tykodi, Scott S; Silk, Ann W; McDermott, David F

细胞生物学

发表日期：2019

文献求助收藏

Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer ("KEYNOTE 045")

评论：帕博利珠单抗作为晚期尿路上皮癌二线疗法的2年随访（“KEYNOTE 045”）

期刊:Translational Andrology and Urology

影响因子:1.7

doi:10.21037/tau.2019.09.19

发表日期：2019

文献求助收藏

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

阿昔替尼联合帕博利珠单抗治疗晚期肾细胞癌患者：一项非随机、开放标签、剂量探索和剂量扩展的 1b 期试验

期刊:Lancet Oncology

影响因子:35.9

doi:10.1016/S1470-2045(18)30081-0

Atkins, Michael B; Plimack, Elizabeth R; Puzanov, Igor; Fishman, Mayer N; McDermott, David F; Cho, Daniel C; Vaishampayan, Ulka; George, Saby; Olencki, Thomas E; Tarazi, Jamal C; Rosbrook, Brad; Fernandez, Kathrine C; Lechuga, Mariajose; Choueiri, Toni K

细胞生物学

发表日期：2018

文献求助收藏

Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer

新辅助化疗方案与接受膀胱切除术治疗的肌层浸润性膀胱癌患者的降期和生存结局相关

期刊:Jama Oncology

影响因子:20.1

doi:10.1001/jamaoncol.2018.3542

Peyton, Charles C; Tang, Dominic; Reich, Richard R; Azizi, Mounsif; Chipollini, Juan; Pow-Sang, Julio M; Manley, Brandon; Spiess, Philippe E; Poch, Michael A; Sexton, Wade J; Fishman, Mayer; Zhang, Jingsong; Gilbert, Scott M

发表日期：2018

文献求助收藏